ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07725
0,00%
Bitcoin
63.647,23
-0,38%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. ImmunoGen Inc (IMGN)

  7. ImmunoGen Inc (IMGN) News

IMGN

ImmunoGen (IMGN)

ImmunoGen Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:IMGN
DatumZeitQuelleÜberschriftSymbolFirma
22/02/202422h15Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:IMGNImmunoGen Inc
14/02/202423h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMGNImmunoGen Inc
14/02/202422h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMGNImmunoGen Inc
12/02/202422h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202422h33Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
12/02/202422h32Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
12/02/202422h27Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
12/02/202422h26Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
12/02/202422h26Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
12/02/202422h25Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
12/02/202422h24Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
12/02/202422h24Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
12/02/202422h23Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
12/02/202422h22Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
12/02/202422h22Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
 Showing the most relevant articles for your search:NASDAQ:IMGN

Kürzlich von Ihnen besucht

DBI
DAX
DAX
TG
BAS
BASF
PM
XAUUSD
Gold vs US Dollar
CCOM
US500
US 500
NASDAQ
TSLA
Tesla
TG
MBG
MercedesBenz
NYSE
JPM
JP Morgan Chase
NASDAQ
QQQ
Invesco QQQ Trust Series 1
DBI
SDXP
SDAX
COIN
BTCUSD
Bitcoin
CCOM
SILVER
SILVER
NYSE
NKE
Nike
FX
EURGBP
Euro vs Sterling
TG
NOV
Novo Nordisk
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten